Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) have earned a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $58.89.

Several brokerages have recently weighed in on IMCR. Needham & Company LLC restated a “buy” rating and set a $71.00 target price on shares of Immunocore in a research note on Thursday, April 10th. Wall Street Zen upgraded Immunocore from a “hold” rating to a “buy” rating in a research note on Saturday, June 14th. Oppenheimer raised their target price on Immunocore from $85.00 to $86.00 and gave the company an “outperform” rating in a research note on Thursday, May 8th. JPMorgan Chase & Co. lowered their target price on Immunocore from $54.00 to $50.00 and set an “overweight” rating for the company in a research note on Monday, April 14th. Finally, Mizuho lowered their target price on Immunocore from $38.00 to $33.00 and set a “neutral” rating for the company in a research note on Monday, April 7th.

Hedge Funds Weigh In On Immunocore

A number of hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC grew its stake in Immunocore by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 35,492 shares of the company’s stock worth $1,047,000 after purchasing an additional 420 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in Immunocore by 1.1% in the first quarter. Envestnet Asset Management Inc. now owns 67,259 shares of the company’s stock valued at $1,996,000 after acquiring an additional 735 shares during the period. GF Fund Management CO. LTD. acquired a new position in Immunocore in the fourth quarter valued at approximately $25,000. NEOS Investment Management LLC boosted its stake in Immunocore by 10.9% in the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock valued at $330,000 after acquiring an additional 1,102 shares during the period. Finally, Assetmark Inc. boosted its stake in Immunocore by 4.8% in the first quarter. Assetmark Inc. now owns 33,710 shares of the company’s stock valued at $1,000,000 after acquiring an additional 1,539 shares during the period. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Immunocore Trading Down 2.8%

NASDAQ:IMCR opened at $31.12 on Friday. The business’s 50-day moving average is $32.06 and its two-hundred day moving average is $30.28. The company has a debt-to-equity ratio of 1.03, a current ratio of 6.36 and a quick ratio of 6.31. Immunocore has a 12 month low of $23.15 and a 12 month high of $41.54. The firm has a market capitalization of $1.56 billion, a PE ratio of -72.37 and a beta of 0.83.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.35) by $0.45. The company had revenue of $125.13 million for the quarter, compared to analyst estimates of $108.82 million. Immunocore had a negative return on equity of 5.86% and a negative net margin of 6.48%. The firm’s revenue was up 33.6% compared to the same quarter last year. During the same period last year, the company posted ($0.49) earnings per share. Research analysts predict that Immunocore will post -0.94 earnings per share for the current fiscal year.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.